Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Details Narrative)

v3.19.1
Basis of Presentation and Significant Accounting Policies (Details Narrative)
$ in Thousands
3 Months Ended 12 Months Ended
Jan. 02, 2019
USD ($)
Mar. 31, 2019
USD ($)
Segment
Dec. 31, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Number of operating segment | Segment   1      
Primary operating account balance   $ 8,571 $ 2,723 $ 1,249 $ 2,723
Cash uninsured amount   50 29   29
Operating lease right-of-use assets and lease liabilities $ 833        
Impairment on IPR&D     53,905    
Research and development in process      
Goodwill   65,195 $ 65,195   $ 65,195
Revenue recognized   5,078    
Research and development expenses   878   877  
Income Tax Expense     $ (419)  
Exclusive License and Research Collaboration Agreement [Member]          
Revenue recognized 5,078        
Exclusive License and Research Collaboration Agreement [Member] | Intellectual Property [Member]          
Revenue recognized 4,368        
Exclusive License and Research Collaboration Agreement [Member] | Research and Development Activities [Member]          
Revenue recognized $ 710        
Exclusive License and Research Collaboration Agreement [Member] | Merck Sharp & Dohme Corp [Member]          
Research and development expenses   755      
U.S. Financial Institutions One [Member]          
Cash FDIC insured limits   250      
U.S. Financial Institutions Two [Member]          
Cash FDIC insured limits   $ 250